Clinical trial NCT02298842: In Vitro Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution
Official title: In Vitro Study of Platelets Collected on Trima Accel System and Stored in InterSol Solution
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Healthy Volunteers
Keywords: Healthy Adults
Lead sponsor: Terumo BCT
Sponsor class: INDUSTRY
First posted: 2014-11-24
Enrollment: 87
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: SUPPORTIVE_CARE

Brief summary: This study sought to verify that the in vitro quality (functional assays) of platelets collected on the Trima Accel system, Version 6.4, diluted in InterSol Solution, and stored for 1, 5, and 7 days meet FDA requirements.

Detailed description: Platelets suspended in platelet additive solutions (PAS) have been collected and transfused in Europe for over 20 years. These PAS solutions outside of the United States (US) are not tied to an apheresis device; however in the US, PAS solutions have traditionally been linked to a corresponding apheresis device.

Currently in the US, there are two solutions approved by the Food and Drug Administration (FDA) as a PAS for the replacement of 65% plasma in platelet components. Isoplate Solution is approved for use with the Trima Accel® Automated Blood Collection System (Trima Accel System) and InterSol Solution is approved for use with the Amicus Separator System.

This study is designed to provide blood centers with the option to use either Isoplate or InterSol when collecting platelets for use with PAS. Terumo BCT is pursuing approval for InterSol Solution in combination with the Trima Accel System.

This is a randomized, paired, prospective, open-label, multi-center study. Up to 120 healthy adult subjects will be enrolled in this study to ensure 60 paired evaluable data points across two Investigational Sites. Evaluable is defined as two completed platelet products with 100mL plasma that do not meet any of the protocol analysis exclusion criteria.

The additional platelet donors account for screen failures, incomplete procedures, and protocol exclusions.

Two units of platelets will be collected from each subject: one Test unit collected as a hyperconcentrated platelet product with 100 mL of concurrent plasma and one Control unit of platelets in plasma collected according to standard procedure. The Test unit will be suspended in 65% Intersol/35% plasma immediately after collection; the Control unit will be maintained in 100% plasma.

Eligible donors who have signed an informed consent will be enrolled. Randomization will occur in a ratio of 1:1 to one of the following Treatment Arms:

Arm A: Collection of one Test unit followed by collection of one Control unit Arm B: Collection of one Control unit followed by collection of one Test unit

The standard apheresis platelet units collected in the Control arm will mirror the hyperconcentrated platelet units in the Test arm in terms of yield and final concentration.

SUBJECT PROCEDURES

Screening can be performed within 30 days of the apheresis procedure or combined with the first Apheresis Visit.

The following evaluations will be performed:

1. Informed consent will be obtained prior to initiating any study specific procedures
2. Eligibility will be confirmed
3. Demographics (age, gender, ethnic origin), height, and weight
4. Complete blood count (CBC) for hemoglobin and platelet count on subjects new to the Investigative Site that do not have historical hemoglobin and/or platelet count measurements

Apheresis Visit

The following procedures will be performed at both the first and second Apheresis Visits:

1. Eligibility will be confirmed
2. Finger stick hemoglobin
3. First apheresis procedure will be performed

Subject will return to the Site in 6 to 8 days following the first apheresis collection for the second apheresis collection. This will conclude the subject's participation.

Apheresis procedures will be run according to the instructions and precautions described in the commercially available Trima Accel Operator's Manual for use with Version 6.4.

The Investigator or designee will perform the venipuncture, monitor the subject during the collection, assess and provide any interventions for adverse effects, remove the needle, dress the puncture site and monitor subject through recovery.

The following will be documented:

1. Trima Procedure details
2. Adverse events
3. Medications to treat AEs
4. Device deficiencies

Eligibility criteria: Inclusion Criteria:

* Age 18 years of age or older
* Meet the inclusion criteria defined by the Investigational Site for an apheresis double platelet with plasma collection on the Trima Accel System. These criteria are based on American Association of Blood Banks (AABB) standards. Note: Subjects who are deferred from volunteer community donations because of travel restrictions, piercings or tattoos may participate in the study.

Exclusion Criteria:

* None.

Primary outcomes:
measure: pH of Platelets at Day 5
timeFrame: Day 5
measure: pH of Platelets at Day 7
timeFrame: Day 7
Secondary outcomes:
measure: Percent of Platelets Activated as Measured by P-selectin
timeFrame: Day 5
measure: Percent of Extent of Shape Change
timeFrame: Day 5
measure: Percent of Platelets Exhibiting Hypotonic Shock Response
timeFrame: Day 5
measure: Platelet Morphology
timeFrame: Day 5
measure: Percent of Platelets Activated as Measured by P-selectin
timeFrame: Day 7
measure: Percent of Extent of Shape Change
timeFrame: Day 7
measure: Percent of Platelets Exhibiting Hypotonic Shock Response
timeFrame: Day 7
measure: Platelet Morphology
timeFrame: Day 7
Other outcomes:
Locations:
city: Cincinnati
country: United States
facility: Hoxworth Blood Center
state: Ohio
city: Milwaukee
country: United States
facility: Blood Center of Wisconsin
state: Wisconsin
Study officials:
affiliation: Hoxworth Blood Center
name: Jose Cancelas-Perez, MD, PhD
role: PRINCIPAL_INVESTIGATOR
affiliation: Clood Center of Wisconsin
name: Mehraboon S Irani, MD
role: PRINCIPAL_INVESTIGATOR
References:
citation: Dumont LJ, Cancelas JA, Graminske S, Friedman KD, Vassallo RR, Whitley PH, Rugg N, Dumont DF, Herschel L, Siegal AH, Szczepiorkowski ZM, Fender L, Razatos A. In vitro and in vivo quality of leukoreduced apheresis platelets stored in a new platelet additive solution. Transfusion. 2013 May;53(5):972-80. doi: 10.1111/j.1537-2995.2012.03841.x. Epub 2012 Aug 6.
citation: Ringwald J, Walz S, Zimmermann R, Zingsem J, Strasser E, Weisbach V, Eckstein R. Hyperconcentrated platelets stored in additive solution: aspects on productivity and in vitro quality. Vox Sang. 2005 Jul;89(1):11-8. doi: 10.1111/j.1423-0410.2005.00645.x.
citation: Cohn CS, Stubbs J, Schwartz J, Francis R, Goss C, Cushing M, Shaz B, Mair D, Brantigan B, Heaton WA. A comparison of adverse reaction rates for PAS C versus plasma platelet units. Transfusion. 2014 Aug;54(8):1927-34. doi: 10.1111/trf.12597. Epub 2014 Apr 16.
citation: Diedrich B, Sandgren P, Jansson B, Gulliksson H, Svensson L, Shanwell A. In vitro and in vivo effects of potassium and magnesium on storage up to 7 days of apheresis platelet concentrates in platelet additive solution. Vox Sang. 2008 Feb;94(2):96-102. doi: 10.1111/j.1423-0410.2007.01002.x. Epub 2007 Nov 22.
citation: Gulliksson H, AuBuchon JP, Vesterinen M, Sandgren P, Larsson S, Pickard CA, Herschel I, Roger J, Tracy JE, Langweiler M; Biomedical Excellence for Safer Transfusion Working Party of the International Society of Blood Transfusion. Storage of platelets in additive solutions: a pilot in vitro study of the effects of potassium and magnesium. Vox Sang. 2002 Apr;82(3):131-6. doi: 10.1046/j.1423-0410.2002.drfgv158.x.
citation: Dumont LJ, VandenBroeke T, Ault KA. Platelet surface P-selectin measurements in platelet preparations: an international collaborative study. Biomedical Excellence for Safer Transfusion (BEST) Working Party of the International Society of Blood Transfusion (ISBT). Transfus Med Rev. 1999 Jan;13(1):31-42. doi: 10.1016/s0887-7963(99)80086-8. No abstract available.